Walid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 30,000 shares of uniQure stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the completion of the transaction, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. This trade represents a 16.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, June 26th, Walid Abi-Saab sold 1,434 shares of uniQure stock. The shares were sold at an average price of $46.86, for a total value of $67,197.24.
• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $41.81 on Friday. The company has a market capitalization of $2.64 billion, a PE ratio of -12.01 and a beta of 0.90. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock has a fifty day moving average of $30.53 and a 200-day moving average of $23.86. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, equities analysts anticipate that uniQure N.V. will post -3.63 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of QURE. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the third quarter worth $50,000. Torren Management LLC acquired a new stake in uniQure during the fourth quarter valued at $28,000. FNY Investment Advisers LLC grew its stake in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares in the last quarter. IFP Advisors Inc purchased a new position in uniQure in the fourth quarter valued at about $48,000. Finally, Knott David M Jr purchased a new position in uniQure in the third quarter valued at about $117,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. HC Wainwright lifted their price target on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. The Goldman Sachs Group raised their target price on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. Chardan Capital lifted their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Leerink Partners lifted their target price on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.